Búsqueda | Biblioteca Virtual en Salud

1.

Obesity and Dyslipidemia.

Nussbaumerova, Barbora; Rosolova, Hana.

Curr Atheroscler Rep ; 25(12): 947-955, 2023 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-37979064

2.

Preventive cardiology: Quo vadis?

Rosolová, Hana.

Vnitr Lek ; 69(2): 76-81, 2023.

Artículo en Inglés | MEDLINE | ID: mdl-37072265

3.

Advances of the contemporary treatment of hypertension and hypercholesterolemia by a new fixed combination.

Rosolová, Hana.

Vnitr Lek ; 68(1): 64-67, 2022.

Artículo en Inglés | MEDLINE | ID: mdl-35459349

4.

New technology in the hypolipidemic drugs development. Inclisiran (LEQVIO).

Rosolová, Hana.

Vnitr Lek ; 68(7): 458-460, 2022.

Artículo en Inglés | MEDLINE | ID: mdl-36402572

5.

Prediabetes.

Rosolová, Hana.

Vnitr Lek ; 68(2): 82-84, 2022.

Artículo en Inglés | MEDLINE | ID: mdl-36208920

6.

How to treat arterial hypertension in obese patients?

Rosolová, Hana.

Vnitr Lek ; 66(8): 490-493, 2020.

Artículo en Inglés | MEDLINE | ID: mdl-33740848

7.

“The higher the better” seems to be no longer true for HDL-cholesterol.

Rosolová, Hana.

Vnitr Lek ; 64(12): 1153-1155, 2019.

Artículo en Inglés | MEDLINE | ID: mdl-30704250

8.

A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis.

Soska, Vladimír; Karásek, David; Bláha, Vladimír; Cífková, Renata; Freiberger, Tomás; Kraml, Pavel; Pitha, Jan; Rosolová, Hana; Stulc, Tomás; Urbanová, Zuzana; Vrablík, Michal.

Vnitr Lek ; 64(12): 1124-1128, 2019.

Artículo en Inglés | MEDLINE | ID: mdl-30704245

9.

A multicentre study on unattended automated office blood pressure measurement in treated hypertensive patients.

Filipovský, Jan; Seidlerová, Jitka; Ceral, Jirí; Vysocanová, Petra; Spác, Jirí; Soucek, Miroslav; Rihácek, Ivan; Materánková, Markéta; König, Petr; Rosolová, Hana.

Blood Press ; 27(4): 188-193, 2018 08.

Artículo en Inglés | MEDLINE | ID: mdl-29334262

10.

Diagnosis of heart failure: the new classification of heart failure.

Nussbaumerová, Barbora; Rosolová, Hana.

Vnitr Lek ; 64(9): 847-851, 2018.

Artículo en Inglés | MEDLINE | ID: mdl-30441997

11.

[Epidemiology of hypercholesterolemia]. / Epidemiologie hypercholesterolemie.

Nussbaumerová, Barbora; Rosolová, Hana.

Vnitr Lek ; 64(1): 30-37, 2018.

Artículo en Cs | MEDLINE | ID: mdl-29498873

12.

[Metabolic syndrome and the role of the polypill in the prevention of its complications]. / Metabolický syndrom a postavení polypilu v prevenci jeho komplikací.

Rosolová, Hana.

Vnitr Lek ; 63(10): 712-716, 2017.

Artículo en Cs | MEDLINE | ID: mdl-29127755

13.

[Obesity paradoxes]. / Paradoxy obezity.

Rosolová, Hana.

Vnitr Lek ; 62(3): 181-2, 2016 Mar.

Artículo en Cs | MEDLINE | ID: mdl-27180664

14.

[The common position of the Czech professional associations on the consensus of the European Atherosclerosis Society and the European Federation of Clinical Chemistry and Laboratory Medicine regarding investigation on blood lipids and interpretation of their levels]. / Spolecné stanovisko ceských odborných spolecností ke konsenzu European Atherosclerosis Society a European Federation of Clinical Chemistry and Laboratory Medicine k vysetrování krevních lipidu a k interpretaci jejich hodnot.

Soska, Vladimír; Franeková, Janka; Friedecký, Bedrich; Jabor, Antonín; Kraml, Pavel; Rosolová, Hana; Vrablík, Michal.

Vnitr Lek ; 62(12): 1034-1040, 2016.

Artículo en Cs | MEDLINE | ID: mdl-28139134

15.

[PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement]. / PCSK9 inhibitory - nové moznosti v lécbe hypercholesterolemie: U koho budou indikovány?Stanovisko Ceské spolecnosti pro aterosklerózu.

Soska, Vladimír; Vrablík, Michal; Bláha, Vladimír; Cífková, Renata; Ceska, Richard; Freiberger, Tomás; Kraml, Pavel; Pitha, Jan; Rosolová, Hana; Stulc, Tomás; Vaverková, Helena; Urbanová, Zuzana.

Vnitr Lek ; 62(4): 329-33, 2016 Apr.

Artículo en Cs | MEDLINE | ID: mdl-27250613

16.

[What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin]. / Co prinásí prehledný clánek o dukazech redukce makrovaskulárního rizika u pacientu s aterogenní dyslipidemií? Zpráva o konsenzu expertu o významu kombinované terapie fenofibrátem a statinem.

Rosolová, Hana.

Vnitr Lek ; 61(11): 971-5, 2015 Nov.

Artículo en Cs | MEDLINE | ID: mdl-26652786

17.

[Residual cardiovascular risk markers]. / Markery reziduálního kardiovaskulárního rizika.

Rosolová, Hana; Nussbaumerová, Barbora.

Vnitr Lek ; 60(11): 937-41, 2014 Nov.

Artículo en Cs | MEDLINE | ID: mdl-25600039

18.

Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.

Blaha, Vladimír; Margoczy, Roman; Petrov, Ivo; Postadzhiyan, Arman; Raslová, Katarína; Rosolová, Hana; Bridges, Ian; Dhalwani, Nafeesa N; Zachlederova, Marie; Ray, Kausik K.

J Cardiovasc Pharmacol Ther ; 28: 10742484231172847, 2023.

Artículo en Inglés | MEDLINE | ID: mdl-37218974

19.

[Physician must grow for preventive medicine. Interview with Prof. Hana Rosolová]. / K preventivní medicíne musí lékar dozrát. Rozhovor s prof. MUDr. Hanou Rosolovou, DrSc.

Rosolová, Hana; Cillíková, Kristýna.

Vnitr Lek ; 60(11): 920-3, 2014 Nov.

Artículo en Cs | MEDLINE | ID: mdl-25612345

20.

High-sensitivity C-reactive protein and the hypertriglyceridemic waist in patients with type 2 diabetes and metabolic syndrome.

Rosolova, Hana; Petrlova, Barbora; Simon, Jaroslav; Sifalda, Pavel; Sipova, Iva.

Med Sci Monit ; 14(8): CR411-5, 2008 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-18667998

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

Obesity and Dyslipidemia.

Preventive cardiology: Quo vadis?

Advances of the contemporary treatment of hypertension and hypercholesterolemia by a new fixed combination.

New technology in the hypolipidemic drugs development. Inclisiran (LEQVIO).

Prediabetes.

How to treat arterial hypertension in obese patients?

“The higher the better” seems to be no longer true for HDL-cholesterol.

A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis.

A multicentre study on unattended automated office blood pressure measurement in treated hypertensive patients.

Diagnosis of heart failure: the new classification of heart failure.

[Epidemiology of hypercholesterolemia]. / Epidemiologie hypercholesterolemie.

[Metabolic syndrome and the role of the polypill in the prevention of its complications]. / Metabolický syndrom a postavení polypilu v prevenci jeho komplikací.

[Obesity paradoxes]. / Paradoxy obezity.

[PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement]. / PCSK9 inhibitory - nové moznosti v lécbe hypercholesterolemie: U koho budou indikovány?Stanovisko Ceské spolecnosti pro aterosklerózu.

[Residual cardiovascular risk markers]. / Markery reziduálního kardiovaskulárního rizika.

Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.

[Physician must grow for preventive medicine. Interview with Prof. Hana Rosolová]. / K preventivní medicíne musí lékar dozrát. Rozhovor s prof. MUDr. Hanou Rosolovou, DrSc.

High-sensitivity C-reactive protein and the hypertriglyceridemic waist in patients with type 2 diabetes and metabolic syndrome.